Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

889 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of fludarabine/melphalan (FM140) with fludarabine/melphalan/BCNU (FBM110) in patients with relapsed/refractory AML undergoing allogeneic hematopoietic cell transplantation - a registry study on behalf of the EBMT Acute Leukemia Working Party.
Duque-Afonso J, Finke J, Ngoya M, Galimard JE, Schetelig J, Eder M, Rösler W, Bug G, Neubauer A, Edinger M, Wulf GG, Jindra P, Einsele H, Stelljes M, Selleslag D, Wagner-Drouet EM, Bunjes D, Spyridonidis A, Brissot E, Nagler A, Ciceri F, Mohty M. Duque-Afonso J, et al. Among authors: finke j. Bone Marrow Transplant. 2024 Dec 19. doi: 10.1038/s41409-024-02499-6. Online ahead of print. Bone Marrow Transplant. 2024. PMID: 39702670
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.
Dreger P, Michallet M, Bosman P, Dietrich S, Sobh M, Boumendil A, Nagler A, Scheid C, Cornelissen J, Niederwieser D, Müller L, Vandenberghe E, Scortechini I, Schoemans H, Andersen NS, Finke J, Russo D, Ljungman P, Passweg J, van Gelder M, Durakovic N, Labussiere-Wallet H, Berg T, Wulf G, Bethge W, Bunjes D, Stilgenbauer S, Canepari ME, Schaap M, Fox CP, Kröger N, Montoto S, Schetelig J. Dreger P, et al. Among authors: finke j. Bone Marrow Transplant. 2019 Jan;54(1):44-52. doi: 10.1038/s41409-018-0207-4. Epub 2018 May 4. Bone Marrow Transplant. 2019. PMID: 29728701 Clinical Trial.
Unmanipulated haploidentical versus HLA-matched sibling allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute myeloid leukemia: a retrospective study on behalf of the ALWP of the EBMT.
Battipaglia G, Boumendil A, Labopin M, Ciceri F, Tischer J, Stelljes M, Ehninger G, Beelen D, Finke J, Van Lint MT, Eder M, Afanasyev B, Fanin R, Mohty M, Ruggeri A, Nagler A. Battipaglia G, et al. Among authors: finke j. Bone Marrow Transplant. 2019 Sep;54(9):1499-1510. doi: 10.1038/s41409-019-0459-7. Epub 2019 Feb 4. Bone Marrow Transplant. 2019. PMID: 30718798 Clinical Trial.
Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT.
Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Ciceri F, Finke J, Bruno B, Bornhäuser M, Gedde-Dahl T, Labussière-Wallet H, Niittyvuopio R, Valerius T, Angelucci E, Brecht A, Caballero D, Kuball J, Potter V, Schmid C, Tischer J, Zuckerman T, Benedetti F, Blaise D, Diez-Martin JL, Sanz J, Ruggeri A, Brissot E, Savani BN, Giebel S, Nagler A, Mohty M. Kharfan-Dabaja MA, et al. Among authors: finke j. Bone Marrow Transplant. 2021 Sep;56(9):2194-2202. doi: 10.1038/s41409-021-01317-7. Epub 2021 Apr 30. Bone Marrow Transplant. 2021. PMID: 33931757
Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT.
Waidhauser J, Labopin M, Esteve J, Kröger N, Cornelissen J, Gedde-Dahl T, Van Gorkom G, Finke J, Rovira M, Schaap N, Petersen E, Beelen D, Bunjes D, Savani B, Schmid C, Nagler A, Mohty M; Acute Leukemia Working Party of EBMT. Waidhauser J, et al. Among authors: finke j. Bone Marrow Transplant. 2021 Oct;56(10):2445-2453. doi: 10.1038/s41409-021-01322-w. Epub 2021 May 31. Bone Marrow Transplant. 2021. PMID: 34059800 Free PMC article.
Impact of conditioning regimen intensity on outcomes of second allogeneic hematopoietic cell transplantation for secondary acute myelogenous leukemia.
Nagler A, Peczynski C, Dholaria B, Labopin M, Valerius T, Dreger P, Kröger N, Reinhardt HC, Finke J, Franke GN, Ciceri F, Verbeek M, Blau IW, Bornhäuser M, Spyridonidis A, Bug G, Bazarbachi A, Schmid C, Yakoub-Agha I, Savani BN, Mohty M. Nagler A, et al. Among authors: finke j. Bone Marrow Transplant. 2022 Jul;57(7):1116-1123. doi: 10.1038/s41409-022-01693-8. Epub 2022 Apr 30. Bone Marrow Transplant. 2022. PMID: 35501565
Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party.
Duque-Afonso J, Finke J, Labopin M, Craddock C, Protheroe R, Kottaridis P, Tholouli E, Byrne JL, Orchard K, Salmenniemi U, Hilgendorf I, Hunter H, Nicholson E, Bloor A, Snowden JA, Verbeek M, Clark A, Savani BN, Spyridonidis A, Nagler A, Mohty M. Duque-Afonso J, et al. Among authors: finke j. Bone Marrow Transplant. 2022 Aug;57(8):1269-1276. doi: 10.1038/s41409-022-01646-1. Epub 2022 May 14. Bone Marrow Transplant. 2022. PMID: 35568756 Free PMC article.
Autologous versus allogeneic hematopoietic cell transplantation for older patients with acute lymphoblastic leukemia. An analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Giebel S, Labopin M, Houhou M, Caillot D, Finke J, Blaise D, Fegueux N, Ethell M, Cornelissen JJ, Forcade E, Yakoub-Agha I, Lussana F, Maertens J, Bourhis JH, Jindra P, Gorin NC, Nagler A, Mohty M. Giebel S, et al. Among authors: finke j. Bone Marrow Transplant. 2023 Apr;58(4):393-400. doi: 10.1038/s41409-022-01904-2. Epub 2023 Jan 7. Bone Marrow Transplant. 2023. PMID: 36611097
Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Abou Dalle I, Labopin M, Kröger N, Schroeder T, Finke J, Stelljes M, Neubauer A, Blaise D, Yakoub-Agha I, Salmenniemi U, Forcade E, Itäla-Remes M, Dreger P, Bug G, Passweg J, Heuser M, Choi G, Brissot E, Giebel S, Nagler A, Ciceri F, Bazarbachi A, Mohty M. Abou Dalle I, et al. Among authors: finke j. Bone Marrow Transplant. 2023 Jul;58(7):784-790. doi: 10.1038/s41409-023-01961-1. Epub 2023 Apr 11. Bone Marrow Transplant. 2023. PMID: 37041215
Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP).
Gavriilaki E, Sakellari I, Labopin M, Bornhäuser M, Hamladji RM, Casper J, Edinger M, Zák P, Yakoub-Agha I, Ciceri F, Schroeder T, Zuckerman T, Kobbe G, Yeshurun M, Narni F, Finke J, Diez-Martin JL, Berceanu A, Hilgendorf I, Verbeek M, Olivieri A, Savani B, Spyridonidis A, Nagler A, Mohty M. Gavriilaki E, et al. Among authors: finke j. Bone Marrow Transplant. 2023 Oct;58(10):1084-1088. doi: 10.1038/s41409-023-02028-x. Epub 2023 Jul 7. Bone Marrow Transplant. 2023. PMID: 37420011
889 results